A Phase 2 interventional study of Midazolam + Ketamine and Dexmedetomidine (DEX) in Emergence Delirium in Pediatric Anesthesia, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Ain Shams University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing midazolam in Emergence Delirium — 4 open to participants now, 5 under way, none of them phase 3. Midazolam · Emergence Delirium.
Among the 11 studies testing midazolam in Emergence Delirium, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 2, and was the 11th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →4 of the 11 studies testing midazolam in Emergence Delirium are open now, in 1 country. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 2–6
Cairo University · Sites in Egypt
Ages 3–10
Esraa Abdel Azez Soltan Mohamed Zayed
Ages 2–12 · Healthy volunteers
By country, each count listing its studies:
Midazolam: first FDA approval 1985 (VERSED), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 60 is below the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 66 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
10 studies in Emergence Delirium by Ain Shams University: 2 open now, 3 under way, 1 of them phase 3. Of 6 finished, 0 (0%) have results posted.
Among the 10 studies in Emergence Delirium by Ain Shams University, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 2, and was the 10th registered.
Ain Shams University’s Emergence Delirium studies by the year they started, since 2018.
3 of the studies testing midazolam in Emergence Delirium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07427446Kasr El Aini HospitalDexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium | 2026-12 |
| NCT07057193Zagazig UniversityEffect of Different Drugs on Emergency Delirium in Preschool Age Patient | 2027-01-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies testing midazolam in Emergence Delirium, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ain Shams University’s 10 in Emergence Delirium:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare the effects of dormicum-ketamine versus dexmedetomidine on postoperative emergence delirium in pediatric patients undergoing deep sedation for burn-related procedures
This prospective randomized controlled study aims to compare the effects of a midazolam-ketamine combination versus dexmedetomidine on postoperative emergence delirium in pediatric patients undergoing deep sedation for burn-related procedures. Eligible pediatric burn patients scheduled for elective dressing changes or minor interventions will be randomly assigned into two equal groups.
Group I (Midazolam-Ketamine group) will receive intravenous midazolam combined with ketamine for deep sedation.
Group II (Dexmedetomidine group) will receive intravenous dexmedetomidine-based sedation according to a standardized dosing protocol.
Standard monitoring will be applied throughout the procedure, and sedation depth will be assessed using a validated sedation scale to ensure comparable levels of deep sedation in both groups. Emergence delirium will be evaluated postoperatively using the Pediatric Anesthesia Emergence Delirium (PAED) scale during recovery.
The primary outcome will be the incidence of emergence delirium in the early postoperative period. Secondary outcomes will include hemodynamic stability, recovery profile, postoperative pain scores, need for rescue medications, and incidence of adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug
Drug: Midazolam + Ketamine
Drug
Drug: Dexmedetomidine (DEX)
Drug pages: MidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants will receive intravenous midazolam (0.05 mg/kg) combined with ketamine (1 mg/kg). Supplemental ketamine doses (0.5 mg/kg) will be administered as needed to maintain adequate deep sedation during burn-related procedures.
Participants will receive intravenous dexmedetomidine (loading dose 1 mcg/kg over 15 minutes, followed by infusion 0.5-1 mcg/kg/hour) adjusted to maintain adequate deep sedation during burn-related procedures.
Incidence of emergence delirium
Incidence of emergence delirium within 30 minutes after the end of anesthesia, defined as a Pediatric Anesthesia Emergence Delirium (PAED) Scale score ≥ 10 at any assessment point. The Pediatric Anesthesia Emergence Delirium (PAED) Scale is a validated instrument ranging from 0 to 20, where higher scores indicate more severe emergence delirium (worse outcome).
Time frame: within 30 minutes after end of anesthesia
Total Opiod requirments
Reduction in perioperative opioid requirement (measured in µg/kg of fentanyl equivalent)
Time frame: Perioperative period
Hemodynamic stability
Hemodynamic stability will be assessed by measuring heart rate (HR) and mean arterial pressure (MAP) at predefined time points. Parameters will include: Mean HR and MAP values Incidence of bradycardia (HR \< age-adjusted normal) Incidence of hypotension (MAP decrease \>20% from baseline)
Time frame: Baseline (pre-sedation), intraoperative period (every 5 minutes), and up to 30 minutes postoperatively
The duration of stay in PACU
The duration of stay in PACU
Time frame: Within 30 minutes after the end of anesthesia, with assessment performed during recovery ( every 5 minutes)
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Ketamine · Dexmedetomidine